Cd83 and allo- and autoimmune conditions
AssigneesRegents of the University of Minnesota, H. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsBrian Betts, Shernan Holtan, Marco Davila
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.
Claims25
A method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof, the method comprising (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.
A method of identifying a subject at risk of developing acute GvHD, the method comprising measuring CD83 in a population of CD4+ T cells from the subject, wherein the presence of CD83 expression in at least 40% of CD4+ T cells in the population or a gMFI of at least 740.5 in the population of CD4+ T cells indicates that the subject is at risk of developing acute GvHD.
A method of identifying a subject at risk of developing chronic GvHD, the method comprising measuring CD83 in a population of CD19+ B cells from the subject, wherein the presence of CD83 expression in at least 19% of CD19+ B cells in the population or a gMFI of at least 396 indicates that the subject is at risk of developing chronic GvHD.
A method of identifying a subject at risk of developing chronic GvHD, the method comprising measuring CD83 in a population of T helper follicular cells from the subject, wherein the presence of CD83 expression in at least 25% of T helper follicular cells in the population or a gMFI of at least 469 indicates that the subject is at risk of developing chronic GvHD.
Dependencies are inferred from the claim text.